spx-303
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 20, 2024 (NCT06259552)
Timeline
No events for the selected filters.
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
- LILRB2INHIBITOR
LILRB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06259552 | Phase 1 | Mar 20, 2024 | — |
Showing 1 of 1 trials
Page 1 / 1